Keyphrases
Carvedilol
100%
Severe Heart Failure
100%
Placebo Groups
30%
Heart Failure
20%
Twice Daily
20%
Quality of Life
20%
Beta-blockers
20%
Placebo-controlled Study
10%
Acute Decompensated Heart Failure
10%
Placebo
10%
Congestive Heart Failure
10%
Cardiac Function
10%
Hospitalization Rate
10%
Multicenter Trial
10%
Follow-up Examination
10%
Mortality Rate
10%
Background Therapy
10%
Left Ventricular Ejection Fraction
10%
Adverse Events
10%
Large Population
10%
Ejection Fraction
10%
Exercise Duration
10%
Current Therapies
10%
Diuretics
10%
Walk Test
10%
Left Ventricular Function
10%
Digoxin
10%
Global Assessment
10%
Distance Traveled
10%
New York Heart Association Classification
10%
Follow-up Time
10%
Short-term Effects
10%
Data Monitoring
10%
Optimal Current
10%
Monitoring Boards
10%
Severe Patients
10%
Severe Impairment
10%
Data Safety
10%
Vasodilating β-blockers
10%
Standard Triple Therapy
10%
Angiotensin-converting Enzyme Inhibitor (ACEi)
10%
Number of Patients
10%
Minnesota Living with Heart Failure Questionnaire (MLHFQ)
10%
Medicine and Dentistry
Carvedilol
100%
Congestive Heart Failure
100%
Placebo
40%
Beta Adrenergic Receptor Blocking Agent
30%
Quality of Life
20%
Heart Function
10%
Placebo-Controlled Study
10%
Evaluation and Follow up
10%
Adverse Event
10%
New York Heart Association Class
10%
Diuretic Agent
10%
Mortality Rate
10%
Ejection Fraction
10%
Heart Left Ventricle Ejection Fraction
10%
ACE Inhibitor
10%
Digoxin
10%
Heart Left Ventricle Function
10%
Walk Test
10%
Nursing and Health Professions
Congestive Heart Failure
100%
Carvedilol
100%
Placebo
40%
Beta Adrenergic Receptor Blocking Agent
30%
Quality of Life
20%
Heart Ejection Fraction
10%
Dipeptidyl Carboxypeptidase Inhibitor
10%
Mortality Rate
10%
New York Heart Association Class
10%
Heart Left Ventricle Ejection Fraction
10%
Adverse Event
10%
Walk Test
10%
Diuretic Agent
10%
Evaluation and Follow up
10%
Placebo-Controlled Study
10%
Digoxin
10%
Pharmacology, Toxicology and Pharmaceutical Science
Carvedilol
100%
Congestive Heart Failure
100%
Placebo
40%
Beta Adrenergic Receptor Blocking Agent
30%
Placebo-Controlled Study
10%
Adverse Event
10%
Dipeptidyl Carboxypeptidase Inhibitor
10%
Diuretic Agent
10%
Mortality Rate
10%
Digoxin
10%